drugset
drugset / Trial / NCT03294707

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

NCT03294707 ↗

Phase 1 Completed 56 enrolled Eidos Therapeutics, a BridgeBio company Celerion · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects

Timeline

Start
2017-09-11
Primary completion
2018-02-05
Completion
2018-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject AG10 Unknown — Oral

Indications

No indication recorded.